当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
ADYNOVATE, Antihemophilic Factor (Recombinant), PEGylated
药品名称
ADYNOVATE, Antihemophilic Factor (Recombinant), PEGylated
承诺描述
Conduct “A phase 3b, prospective, open label, and multicentercontinuation study of safety and efficacy of ADYNOVATE in the routine prophylaxis of bleeding to reduce the frequency of bleeding episodes in PTPs” age 12 years and above [clinical study 261302].